NEW YORK (GenomeWeb News) – Celera Genomics and Applied Biosystems are looking to sell some California real estate.
Celera Genomics is seeking to sell a 44,000-square-foot facility in South San Francisco that had been used for its scuttled small-molecule drug-discovery efforts, the company said in a Securities and Exchange Commission filing yesterday.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.